TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34836205

Group type: EXPERIMENTAL
Intervention: Xylitol (8 g three times a day for five to seven weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Erythritol (12 g three times a day for five to seven weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no substance)
Number of subjects: 46
Study: 32580282

Group type: EXPERIMENTAL
Intervention: Low-calorie ketogenic diet (LCKD)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 91
Study: 36099069

Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin (Saxa+Met)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Saxagliptin + Acarbose (Saxa+Aca)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Saxagliptin + Gliclazide MR (Saxa+Gli)
Number of subjects: 648
Study: 32910141

Group type: EXPERIMENTAL
Intervention: Reslizumab (1.0 mg/kg IV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: DEC treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reslizumab and Placebo
Number of subjects: 8
Study: 36078306

Group type: EXPERIMENTAL
Intervention: Cooperative learning group
Number of subjects: 216

Group type: COMPARATOR
Intervention: Individual learning group
Number of subjects: 216
Study: 34922447

Group type: EXPERIMENTAL
Intervention: Pragmatic combination of behavioural science and evidence-based techniques in study invitation letter
Number of subjects: 2702

Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 2702
Study: 32427788

Group type: EXPERIMENTAL
Intervention: Highly hydrophilic polyurethane (HHP) foam dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Early hydrophilic polyurethane (EHP) foam dressing
Number of subjects: 20
Study: 35573797

Group type: EXPERIMENTAL
Intervention: Risk score based on clinical factors and lymphocyte subtyping including CD8+ T-cell count ≤143 cells/mm3, high-dose corticosteroids (≥50 mg prednisolone equivalent), carbapenem/tigecycline, APACHE II score ≥15, (1,3)-β-D-glucan positivity, emergency gastrointestinal/hepatobiliary surgery.
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Risk score categorization: low risk (0-2 points), moderate risk (3-4 points), high risk (5-7 points).
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Predictive scoring system using clinical factors and CD8+ T cell count.
Number of subjects: 1054
Study: 33656446

Group type: EXPERIMENTAL
Intervention: Tunnel IA design
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Matrix IA design
Number of subjects: 215

Group type: COMPARATOR
Intervention: Hierarchical IA design
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Knowledge gain
Number of subjects: 215
Study: 35648299

Group type: EXPERIMENTAL
Intervention: Screen-detected ER+ tumours
Number of subjects: 62378

Group type: COMPARATOR
Intervention: Most deprived quintile
Number of subjects: 62378

Group type: COMPARATOR
Intervention: Luminal A tumours in the most deprived quintile
Number of subjects: 62378

Group type: COMPARATOR
Intervention: HER2−enriched tumours in the most deprived quintile
Number of subjects: 62378

Group type: COMPARATOR
Intervention: Luminal B and TNBC tumours in the most deprived quintile
Number of subjects: 62378
Study: 34043229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tanezumab 5mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5mg titrated to 5mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug
Number of subjects: 150
Study: 32152886

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Indirect laryngoscopy
Number of subjects: 34
Study: 34997371

Group type: EXPERIMENTAL
Intervention: 18% SF6
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 16% C2F6
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 12% C3F8
Number of subjects: 159
Study: 33787584

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol) 100,000 IU
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 32799994

Group type: EXPERIMENTAL
Intervention: Occupational therapy interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expert opinion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case series
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case-controlled studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cohort studies
Number of subjects: 0
Study: 32762632

Group type: EXPERIMENTAL
Intervention: Labral repair/refixation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rim trimming
Number of subjects: 12

Group type: COMPARATOR
Intervention: Separated CLJ (CLJ Cut group)
Number of subjects: 12
Study: 35487873

Group type: EXPERIMENTAL
Intervention: HLA-G +3142GG genotype in alloimmunized patients with antibodies against Rh and Kell antigens
Number of subjects: 213

Group type: COMPARATOR
Intervention: HLA-G +14 bp Ins/Del and +3142 C>G variations
Number of subjects: 213
Study: 33420472

Group type: EXPERIMENTAL
Intervention: Nut-enriched low-calorie diet (NELCD)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nut-free low-calorie diet (NFLCD)
Number of subjects: 67
Study: 32423746

Group type: EXPERIMENTAL
Intervention: Vidian neurectomy
Number of subjects: 112
Study: 34031332

Group type: EXPERIMENTAL
Intervention: Predicted emmetropia (EM) group
Number of subjects: 139

Group type: COMPARATOR
Intervention: Predicted residual myopia (RM) group
Number of subjects: 139
Study: 33867409

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4018

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 4018
Study: 35329235

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3x/week, moderate-intensity)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-intensity stretching and breathing (control)
Number of subjects: 30
Study: 35067719

Group type: EXPERIMENTAL
Intervention: TTA-121 6 U/day
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 34787727

Group type: EXPERIMENTAL
Intervention: Judo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ball games (soccer, volleyball, handball, basketball)
Number of subjects: 65
Study: 36143896

Group type: EXPERIMENTAL
Intervention: McConnell taping
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 52
Study: 34007136

Group type: EXPERIMENTAL
Intervention: Computed tomography radiomics model
Number of subjects: 185

Group type: COMPARATOR
Intervention: Image features
Number of subjects: 185
Study: 32698912

Group type: EXPERIMENTAL
Intervention: Calanus finmarchicus oil (CO) 2g daily providing 124 mg stearidonic acid, 109 mg EPA, and 87 mg DHA
Number of subjects: 72

Group type: COMPARATOR
Intervention: Exercise only (Control group)
Number of subjects: 72
Study: 35048203

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 50
Study: 34175784

Group type: EXPERIMENTAL
Intervention: Varenicline plus naltrexone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Varenicline alone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 32470710

Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa2b (PEG-IFNα-2b) at 3 μg/kg/week subcutaneously for 2 years
Number of subjects: 112

Group type: COMPARATOR
Intervention: observation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa2b (PEG-IFNα-2b)
Number of subjects: 112
Study: 34765950

Group type: EXPERIMENTAL
Intervention: GM1 (60 mg daily for 3 weeks or 40 mg daily for 2 weeks)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 33176853

Group type: EXPERIMENTAL
Intervention: Making Mindfulness Matter (M3) intervention, delivered online over 8 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control group, no intervention during the 8 weeks.
Number of subjects: 100
Study: 33543381

Group type: COMPARATOR
Intervention: Subgingival debridement (SD) alone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Subgingival debridement (SD) with light-activated disinfection (LAD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subgingival debridement (SD) with light-activated disinfection (LAD) plus probiotic treatment
Number of subjects: 48
Study: 34797439

Group type: EXPERIMENTAL
Intervention: Slightly warm (iTS=1, n=50)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Warm-to-hot (iTS=2/3, n=44)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Neutral (iTS=0, n=11)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control condition (15.8 ± 1.2 °C, 55 ± 6% RH)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tokyo condition (31.6 ± 1.0 °C, 74 ± 5% RH)
Number of subjects: 105
Study: 32924566

Group type: EXPERIMENTAL
Intervention: Group $5/$5
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Group $5/$10
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Group $10/$0
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Group $10/$5
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Group $10/$10
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Second incentives (various amounts)
Number of subjects: 1500
Study: 33839586

Group type: EXPERIMENTAL
Intervention: Obesity and eating disorder prevention interventions
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 364
Study: 35118795

Group type: EXPERIMENTAL
Intervention: mi. spot (n=22)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wait list control group (n=19)
Number of subjects: 41
Study: 32379634

Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 80
Study: 32921680

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day add-on
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional therapy add-on
Number of subjects: 78
Study: 36153496

Group type: EXPERIMENTAL
Intervention: Atezolizumab maintenance therapy with thoracic radiotherapy (TRT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Atezolizumab maintenance therapy without thoracic radiotherapy (TRT)
Number of subjects: 104
Study: 32017598

Group type: EXPERIMENTAL
Intervention: VL10%
Number of subjects: 25

Group type: COMPARATOR
Intervention: VL30%
Number of subjects: 25
Study: 34991570

Group type: EXPERIMENTAL
Intervention: CDS
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: CDS + SDMT
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 166
Study: 33446564

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-059)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-061)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-061)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-062)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-062)
Number of subjects: 191
Study: 35926795

Group type: EXPERIMENTAL
Intervention: PCEA with 0.06% bupivacaine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PAI
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PAI + PCEA with 0.06% bupivacaine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 180
Study: 34185259

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously every 3–4 weeks for about 6 months and then every 3 months for a total treatment duration of 5 years
Number of subjects: 4509

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously
Number of subjects: 4509
Study: 33032163

Group type: EXPERIMENTAL
Intervention: Floatation‐restricted environmental stimulation therapy (floatation‐REST)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no floatation‐REST)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Floatation‐REST
Number of subjects: 9
Study: 34170235

Group type: EXPERIMENTAL
Intervention: Nurse-communicated management
Number of subjects: 200

Group type: COMPARATOR
Intervention: Physician-led management
Number of subjects: 200
Study: 34481724

Group type: EXPERIMENTAL
Intervention: NSS-2 BRIDGE device (NBD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 34298028

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Framing-text messages (SMS)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 918
Study: 32174571

Group type: EXPERIMENTAL
Intervention: Split conjunctival autograft with limbus to limbus orientation (Group 1)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Split conjunctival autograft without limbus to limbus orientation (Group 2)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 192
Study: 34159460

Group type: EXPERIMENTAL
Intervention: Super-low volume polyethylene glycol (PEG) for 3 days followed by low volume PEG on examination day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Senna laxative for 3 days followed by low volume PEG on examination day
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Super-low volume polyethylene glycol (PEG)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Senna laxative
Number of subjects: 250
Study: 34521554

Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m2 1-h i.v. infusion q3wk
Number of subjects: 442

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 1-h i.v. infusion q4wk or topotecan 1.50 mg/m2 30-min i.v. infusion Days 1-5 q3wk
Number of subjects: 442
Study: 33200180

Group type: EXPERIMENTAL
Intervention: Diet-related interventions (diet and/or behavioral manipulation, provision of foods or entire meals, or delivery of dietary components in individual food items or supplements)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human nutrition RCTs
Number of subjects: 0
Study: 34124999

Group type: EXPERIMENTAL
Intervention: One-time tailored information on vaccination schedule
Number of subjects: 534

Group type: COMPARATOR
Intervention: Generic information on vaccination schedule
Number of subjects: 534
Study: 33878954

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy plus pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy followed by pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care adjuvant platinum-based chemotherapy
Number of subjects: 0
Study: 33009045

Group type: EXPERIMENTAL
Intervention: Risk assessment via CCRAT
Number of subjects: 230

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 230
Study: 33066601

Group type: EXPERIMENTAL
Intervention: Pre-exercise music trial (T2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simultaneous music trial (T3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-music trial (T1)
Number of subjects: 20
Study: 35238401

Group type: EXPERIMENTAL
Intervention: General anaesthesia (target‐controlled total intravenous anaesthesia with propofol and remifentanil)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (bilateral scalp block with remifentanil sedation if required)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 60
Study: 35948843

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 34312943

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis C‐3102 supplemented milk replacer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no Bacillus subtilis C‐3102)
Number of subjects: 12
Study: 35292486

Group type: EXPERIMENTAL
Intervention: 3-hour training for neurologists on how to provide complex information about MS escalation therapy
Number of subjects: 34
Study: 32788041

Group type: EXPERIMENTAL
Intervention: Subcutaneous border plating (± hook)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Supraspinatus fossa plating (± hook)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Presence of the lateral plate hook
Number of subjects: 24
Study: 35300506

Group type: EXPERIMENTAL
Intervention: Azelastine add-on therapy and Budesonide nasal spray
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Montelukast add-on therapy and Budesonide nasal spray
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intranasal Budesonide spray with placebo tablet (Control)
Number of subjects: 66
Study: 35738244

Group type: EXPERIMENTAL
Intervention: 6 months of Dialectical Behavior Therapy (DBT-6)
Number of subjects: 240

Group type: COMPARATOR
Intervention: 12 months of Dialectical Behavior Therapy (DBT-12)
Number of subjects: 240
Study: 32667270

Group type: EXPERIMENTAL
Intervention: MACI
Number of subjects: 21

Group type: COMPARATOR
Intervention: ACI-P
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 35062872

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA) group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Multimodal analgesia (MMA) group
Number of subjects: 103
Study: 33823285

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova‐T) 0.3 mg/kg every 6 weeks (omitted every third cycle)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova‐T)
Number of subjects: 748
Study: 32645213

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (maximum dose = 12 mg/d)
Number of subjects: 858
Study: 36167895

Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 1.2 mmol L‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 2.4 mmol L‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 3.6 mmol L‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 1.2, 2.4, and 3.6 mmol L‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Silicon (Si) at all concentrations (1.2, 2.4, and 3.6 mmol L‐1)
Number of subjects: 6
Study: 33821932

Group type: EXPERIMENTAL
Intervention: Standard Patient Information Leaflet (PIL)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Positively framed Patient Information Leaflet (PIL)
Number of subjects: 203
Study: 32083357

Group type: EXPERIMENTAL
Intervention: 1-minute CO2 stimulus duration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2-minute CO2 stimulus duration
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4-minute CO2 stimulus duration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5-minute CO2 stimulus duration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VE-CO2 sensitivity from 1-minute to 4- and 5-minute durations
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 4-minute and 5-minute steady-state time-points
Number of subjects: 18
Study: 36419123

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure at 150 µg/m3 PM2.5 for 4 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure at varying concentrations (20, 50, 150 µg/m3 PM2.5)
Number of subjects: 17
Study: 32540235

Group type: EXPERIMENTAL
Intervention: Taxane
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 0
Study: 36038705

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 5 cycles of 3 min at 80% peak oxygen uptake alternating with 3 min at 40% peak oxygen uptake
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate-Intensity Steady-State Exercise (MISS) - 30 min at 60% peak oxygen uptake
Number of subjects: 16
Study: 33880724

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) - 3D conformal external irradiation, 3.75 Gy/fraction, twice a day, 5 fractions/week, total dose 37.5 Gy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) - 3D conformal external irradiation, 2 Gy daily/fraction, 5 fractions/week, total dose 50 Gy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: APBI
Number of subjects: 86

Group type: COMPARATOR
Intervention: WBI
Number of subjects: 86
Study: 32492153

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol; 2000 IU/day)
Number of subjects: 25871
Study: 35124517

Group type: EXPERIMENTAL
Intervention: Hamstring flexibility (positive on the forward bending task, n = 17)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (negative on the forward bending task, n = 17)
Number of subjects: 140
Study: 34077499

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Blood Glucose Meter (BGM)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: CGM
Number of subjects: 175

Group type: COMPARATOR
Intervention: BGM
Number of subjects: 175
Study: 33322629

Group type: EXPERIMENTAL
Intervention: Bovine milk-based multicomponent fortifier and protein supplement
Number of subjects: 103

Group type: COMPARATOR
Intervention: Donkey milk-derived multicomponent fortifier and protein supplement
Number of subjects: 103
Study: 32984909

Group type: EXPERIMENTAL
Intervention: Oral plus intravenous (IV) antibiotic prophylaxis (AP) - oral erythromycin 500 mg + metronidazole 500 mg a day before surgery and 1,000 mg of cephalosporin IV 30–90 min before operation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Intravenous (IV) antibiotic prophylaxis only
Number of subjects: 116
Study: 32184315

Group type: EXPERIMENTAL
Intervention: Pain Squad+ smartphone app
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pain Squad+ smartphone app with nurse support
Number of subjects: 74

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 74
Study: 35688408

Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction (HFpEF)
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Heart failure with reduced ejection fraction (HFrEF)
Number of subjects: 7141
Study: 34737864

Group type: EXPERIMENTAL
Intervention: Sugar intervention video
Number of subjects: 4013

Group type: COMPARATOR
Intervention: Sunscreen content placebo video
Number of subjects: 4013

Group type: COMPARATOR
Intervention: Earthquake placebo video
Number of subjects: 4013